Russell Investments Group Ltd. Decreases Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Russell Investments Group Ltd. decreased its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLSGet Rating) by 55.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,749 shares of the company’s stock after selling 60,202 shares during the period. Russell Investments Group Ltd.’s holdings in Apellis Pharmaceuticals were worth $2,424,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Virginia Retirement Systems ET AL boosted its position in shares of Apellis Pharmaceuticals by 7.1% in the first quarter. Virginia Retirement Systems ET AL now owns 6,000 shares of the company’s stock worth $305,000 after buying an additional 400 shares during the period. Virtus ETF Advisers LLC boosted its position in shares of Apellis Pharmaceuticals by 23.7% in the fourth quarter. Virtus ETF Advisers LLC now owns 8,725 shares of the company’s stock worth $413,000 after buying an additional 1,673 shares during the period. ProShare Advisors LLC boosted its position in shares of Apellis Pharmaceuticals by 8.4% in the fourth quarter. ProShare Advisors LLC now owns 29,151 shares of the company’s stock worth $1,377,000 after buying an additional 2,257 shares during the period. Pictet & Cie Europe SA boosted its holdings in Apellis Pharmaceuticals by 43.2% in the first quarter. Pictet & Cie Europe SA now owns 9,069 shares of the company’s stock valued at $461,000 after purchasing an additional 2,734 shares during the last quarter. Finally, Dupont Capital Management Corp purchased a new position in Apellis Pharmaceuticals in the first quarter valued at about $161,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Apellis Pharmaceuticals Stock Up 3.8 %

Shares of Apellis Pharmaceuticals stock opened at $67.95 on Monday. The company has a current ratio of 7.57, a quick ratio of 8.58 and a debt-to-equity ratio of 0.57. The business’s 50 day simple moving average is $50.01 and its 200-day simple moving average is $47.37. The stock has a market capitalization of $7.47 billion, a price-to-earnings ratio of -10.04 and a beta of 1.54. Apellis Pharmaceuticals, Inc. has a twelve month low of $27.50 and a twelve month high of $68.87.

Apellis Pharmaceuticals (NASDAQ:APLSGet Rating) last announced its quarterly earnings results on Monday, August 8th. The company reported ($1.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.03). Apellis Pharmaceuticals had a negative return on equity of 272.25% and a negative net margin of 660.59%. During the same period last year, the firm earned ($2.72) EPS. Equities research analysts forecast that Apellis Pharmaceuticals, Inc. will post -5.9 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on APLS. Raymond James increased their price target on Apellis Pharmaceuticals from $102.00 to $113.00 and gave the company a “strong-buy” rating in a report on Tuesday, August 9th. Credit Suisse Group increased their price target on Apellis Pharmaceuticals from $49.00 to $52.00 and gave the company a “neutral” rating in a report on Tuesday, August 9th. HC Wainwright began coverage on Apellis Pharmaceuticals in a report on Tuesday, July 19th. They issued a “buy” rating and a $75.00 price target for the company. Citigroup increased their price target on Apellis Pharmaceuticals from $81.00 to $86.00 and gave the company a “buy” rating in a report on Wednesday, July 20th. Finally, Stifel Nicolaus initiated coverage on Apellis Pharmaceuticals in a report on Thursday, June 16th. They issued a “buy” rating for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Apellis Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $72.64.

Insider Transactions at Apellis Pharmaceuticals

In related news, Director A. Sinclair Dunlop sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 23rd. The stock was sold at an average price of $45.00, for a total value of $675,000.00. Following the sale, the director now directly owns 285,679 shares in the company, valued at approximately $12,855,555. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, insider Adam J. Townsend sold 12,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 11th. The stock was sold at an average price of $67.00, for a total value of $837,500.00. Following the sale, the insider now directly owns 42,907 shares in the company, valued at approximately $2,874,769. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director A. Sinclair Dunlop sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 23rd. The shares were sold at an average price of $45.00, for a total value of $675,000.00. Following the completion of the sale, the director now owns 285,679 shares in the company, valued at $12,855,555. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 148,039 shares of company stock worth $7,840,735. 8.00% of the stock is currently owned by company insiders.

About Apellis Pharmaceuticals

(Get Rating)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company’s lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases.

See Also

Want to see what other hedge funds are holding APLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apellis Pharmaceuticals, Inc. (NASDAQ:APLSGet Rating).



Receive News & Ratings for Apellis Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *